Expert Ratings For Agios Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Agios Pharmaceuticals (NASDAQ:AGIO) has been analyzed by 4 analysts in the last three months, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased by 30.91% to $46.25. Key analysts from JP Morgan, Goldman Sachs, and RBC Capital have provided recent evaluations, with some raising their price targets.
June 17, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agios Pharmaceuticals has received mixed analyst ratings over the past three months, with an average 12-month price target increase of 30.91% to $46.25. Analysts from JP Morgan, Goldman Sachs, and RBC Capital have provided recent evaluations, with some raising their price targets.
The increase in the average 12-month price target by 30.91% and the recent evaluations from key analysts suggest a positive short-term outlook for Agios Pharmaceuticals. The mixed ratings indicate some uncertainty, but the overall trend is upward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100